- Home
- CPHC vs INKT Comparison
CPHC vs INKT Comparison
Compare CPHC & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPHC
- INKT
- Stock Information
- Founded
- CPHC 1994
- INKT 2017
- Country
- CPHC United States
- INKT United States
- Employees
- CPHC N/A
- INKT N/A
- Industry
- CPHC Services-Misc. Amusement & Recreation
- INKT Medicinal Chemicals and Botanical Products
- Sector
- CPHC Consumer Discretionary
- INKT Health Care
- Exchange
- CPHC Nasdaq
- INKT Nasdaq
- Market Cap
- CPHC 92.5M
- INKT 75.7M
- IPO Year
- CPHC 1994
- INKT 2021
- Fundamental
- Price
- CPHC $18.00
- INKT $11.80
- Analyst Decision
- CPHC
- INKT Hold
- Analyst Count
- CPHC 0
- INKT 3
- Target Price
- CPHC N/A
- INKT $37.50
- AVG Volume (30 Days)
- CPHC 1.4K
- INKT 3.0M
- Earning Date
- CPHC 08-15-2025
- INKT 08-14-2025
- Dividend Yield
- CPHC 1.55%
- INKT N/A
- EPS Growth
- CPHC N/A
- INKT N/A
- EPS
- CPHC 0.16
- INKT N/A
- Revenue
- CPHC $60,605,931.00
- INKT N/A
- Revenue This Year
- CPHC N/A
- INKT N/A
- Revenue Next Year
- CPHC N/A
- INKT N/A
- P/E Ratio
- CPHC $111.77
- INKT N/A
- Revenue Growth
- CPHC N/A
- INKT N/A
- 52 Week Low
- CPHC $16.75
- INKT $4.56
- 52 Week High
- CPHC $22.93
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- CPHC 44.52
- INKT 44.92
- Support Level
- CPHC $17.94
- INKT $12.30
- Resistance Level
- CPHC $18.65
- INKT $20.25
- Average True Range (ATR)
- CPHC 0.19
- INKT 1.69
- MACD
- CPHC -0.05
- INKT -1.22
- Stochastic Oscillator
- CPHC 9.72
- INKT 3.41
About CPHC Canterbury Park Holding Corporation 'New'
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.